spbmedicalrecordsНовые Санкт-Петербургские врачебные ведомостиNew St. Petersburg Medical Records1609-2201Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова10.24884/1609-2201-2024-103-3-50-55spbmedicalrecords-34Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSОбетихолевая кислота в лечении заболеваний гепатобилиарной системыObeticholic acid for the treatment of hepatobiliary disordershttps://orcid.org/0000-0002-4690-1811ПриходькоВ. А.PrikhodkoV. A.

Вероника Александровна Приходько, кандидат биологических наук, старший преподаватель кафедры фармакологии и клинической фармакологии,

197376, Санкт-Петербург, ул. Профессора Попова, д. 14, лит. А.

Veronika A. Prikhodko, Cand. of Sci. (Biol.), Senior Lecturer of the Department of Pharmacology and Clinical Pharmacology

14A Professora Popova str., Saint Petersburg, 197376

veronika.prihodko@pharminnotech.comhttps://orcid.org/0009-0000-2629-683XКарелинаЕ. А.KarelinaE. A.

Екатерина Андреевна Карелина, студент фармацевтического факультета

Санкт-Петербург

Ekaterina A. Karelina, Student of the Pharmaceutical Faculty

Saint Petersburg

ekaterina.karelina@spcpu.ruhttps://orcid.org/0000-0003-4294-5531ОковитыйС. B.OkovityiS. V.

Сергей Владимирович Оковитый, доктор медицинских наук, профессор, заведующий кафедрой фармакологии и клинической фармакологии, Санкт-Петербургский государственный химико-фармацевтический университет; профессор научно-клинического и образовательного центра гастроэнтерологии и гепатологии, Санкт-Петербургский государственный университет

Санкт-Петербург

Sergey V. Okovityi, Dr. of Sci. (Med.), Professor, Head of the Department of Pharmacology and Clinical Pharmacology, Saint Petersburg State Chemical and Pharmaceutical University; Professor at the Scientific and Clinical Center for Gastroenterology and Hepatology, Saint Petersburg State University

Saint Petersburg

Санкт-Петербургский государственный химико-фармацевтический университетРоссияSaint Petersburg State Chemical and Pharmaceutical UniversityRussian FederationСанкт-Петербургский государственный химико-фармацевтический университет; Санкт-Петербургский государственный университетРоссияSaint Petersburg State Chemical and Pharmaceutical University; Saint Petersburg State UniversityRussian Federation202428012025035055Copyright © Приходько В.А., Карелина Е.А., Оковитый С.B., 20252025Приходько В.А., Карелина Е.А., Оковитый С.B.Prikhodko V.A., Karelina E.A., Okovityi S.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.docved.ru/jour/article/view/34

Обетихолевая кислота — первый представитель класса селективных агонистов фарнезоидного X-рецептора, зарегистрированный за рубежом (с августа 2024 г. — и в РФ) для лечения первичного билиарного холангита у больных с субоптимальным ответом на монотерапию урсодезоксихолевой кислотой или ее непереносимостью. Настоящий обзор посвящен особенностям и перспективам применения препаратов обетихолевой кислоты как при первичном билиарном холангите, так и других заболеваниях гепатобилиарной системы, включая неалкогольный (метаболически-ассоциированный) стеатогепатит

Obeticholic acid is the first-in-class selective farnesoid X receptor agonist that is approved in several countries (since August 2024, including Russia) for the treatment of primary biliary cholangitis in patients with inadequate response to monotherapy with ursodeoxycholic acid or intolerance thereof. The present paper reviews the aspects and prospects of the use of obeticholic acid in primary biliary cholangitis as well as other hepatobiliary diseases, including non-alcoholic (metabolic dysfunction-associated) steatohepatitis.

обетихолевая кислотапервичный билиарный холангитагонисты фарнезоидного X-рецепторахолестатические заболевания печенинеалкогольный стеатогепатитгепатобилиарная системаobeticholic acidprimary biliary cholangitisfarnesoid X receptor agonistscholestatic liver diseasenonalcoholic steatohepatitishepatobiliary systemReferencesTrivella J., John B. V., Levy C. Primary biliary cholangitis: Epidemiology, prognosis, and treatment // Hepatol Commun. 2023. Vol. 7, № 6. P. e0179. https://doi.org/10.1097/HC9.0000000000000179.Trivella J., John B. V., Levy C. Primary biliary cholangitis: Epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7(6):e0179. https://doi.org/10.1097/HC9.0000000000000179.Винницкая Е. В., Абсандзе К. Г., Архипова Е. В. и др. Первичный билиарный холангит в эпоху урсодезоксихолевой кислоты: достижения и проблемы терапии // Доктор.Ру. 2019. №3 (158). С. 33–39.Vinnitskaya E. V., Absandze K. G., Arkhipova E. V. et al. Primary biliary cholangitis and ursodeoxycholic acid: therapy progress and challenges. Doctor.Ru. 2019;(3(158)):33–39. (In Russ.). https://doi.org/10.31550/1727-2378-2019-158-3-33-39.Chalifoux S. L., Konyn P. G., Choi G., Saab S. Extrahepatic manifestations of primary biliary cholangitis // Gut Liver. 2017. Vol. 11, № 6. P. 771–780. https://doi.org/10.5009/gnl16365.Chalifoux S. L., Konyn P. G., Choi G., Saab S. Extrahepatic manifestations of primary biliary cholangitis. Gut Liver. 2017;11(6):771–780. https://doi.org/10.5009/gnl16365.Ивашкин В. Т., Широкова Е. Н., Маевская М. В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015. Т. 25, № 2. С. 41–57.Ivashkin V. T., Shirokova Ye. N., Mayevskaya M. V. et al. Clinical guidelines of the Russian gastroenterological association and the Russian society on study of the liver on diagnostics and treatment of cholestasis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(2):41–57. (In Russ.).European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis J Hepatol. 2017;67(1):145–172. https://doi.org/10.1016/j.jhep.2017.03.022.European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–172. https://doi.org/10.1016/j.jhep.2017.03.022.Lindor K. D., Bowlus C. L., Boyer J. et al. Primary biliary cholangitis: 2018 practice guidance from the american association for the study of liver diseases // Hepatology. 2019. Vol. 69, № 1. P. 394–419. https://doi.org/10.1002/hep.30145.Lindor K. D., Bowlus C. L., Boyer J. et al. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases. Hepatology. 2019;69(1):394–419. https://doi.org/10.1002/hep.30145.United States Food and Drugs Administration. Ocaliva (obeticholic acid): Approval label. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf (accessed: 2.09.2024).United States Food and Drugs Administration. Ocaliva (obeticholic acid): Approval label. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf (accessed: 2.09.2024).Fiorucci S., Clerici C., Antonelli E. et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis // J Pharmacol Exp Ther. 2005. Vol. 313, № 2. P. 604–612. https://doi.org/10.1124/jpet.104.079665.Fiorucci S., Clerici C., Antonelli E. et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther. 2005;313(2):604–612. https://doi.org/10.1124/jpet.104.079665.Jiang L., Liu X., Liang X. et al. Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA // Comput Struct Biotechnol J. 2023. Vol. 21. P. 3149–3157. https://doi.org/10.1016/j.csbj.2023.05.026.Jiang L., Liu X., Liang X. et al. Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA. Comput Struct Biotechnol J. 2023;21:3149–3157. https://doi.org/10.1016/j.csbj.2023.05.026.Floreani A., Gabbia D., De Martin S. Obeticholic acid for primary biliary cholangitis // Biomedicines. 2022. Vol. 10, № 10. P. 2464. https://doi.org/10.3390/biomedicines10102464.Floreani A., Gabbia D., De Martin S. Obeticholic acid for primary biliary cholangitis. Biomedicines. 2022;10(10):2464. https://doi.org/10.3390/biomedicines10102464.Keshvani C., Kopel J., Goyal H. Obeticholic Acid – A Pharmacological and Clinical Review // Future Pharmacology. 2023. Vol. 3, № 1. P. 238–251. https://doi.org/10.3390/futurepharmacol3010017.Keshvani C., Kopel J., Goyal H. Obeticholic Acid – A pharmacological and clinical review. Future Pharmacology. 2023;3(1):238–251. https://doi.org/10.3390/futurepharmacol3010017.Mi L. Z., Devarakonda S., Harp J. M. et al. Structural basis for bile acid binding and activation of the nuclear receptor FXR // Mol Cell. 2003. Vol. 11, № 4. P. 1093–1100. https://doi.org/10.1016/s1097-2765, № 03)00112-6.Mi L. Z., Devarakonda S., Harp J. M. et al. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell. 2003;11(4):1093–1100. https://doi.org/10.1016/s10972765(03)00112-6.Khanna A., Jones D. E. Novel strategies and therapeutic options for the management of primary biliary cholangitis // Therap Adv Gastroenterol. 2017. Vol. 10, № 10. P. 791–803. https://doi.org/10.1177/1756283X17728669.Khanna A., Jones D. E. Novel strategies and therapeutic options for the management of primary biliary cholangitis. Therap Adv Gastroenterol. 2017;10(10):791–803. https://doi.org/10.1177/1756283X17728669.Nevens F., Andreone P., Mazzella G. et al. POISE Study Group. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis // N Engl J Med. 2016. Vol. 375, № 7. P. 631–643. https://doi.org/10.1056/NEJMoa1509840Nevens F., Andreone P., Mazzella G. et al. POISE Study Group. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med. 2016;375(7):631–643. https://doi.org/10.1056/NEJMoa1509840United States Food and Drugs Administration. Ocaliva (obeticholic acid): Package insert. 2022. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207999s008lbl.pdf (accessed: 2.09.2024).United States Food and Drugs Administration. Ocaliva (obeticholic acid): Package insert. 2022. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207999s008lbl.pdf (accessed: 2.09.2024).Edwards J. E., Eliot L., Parkinson A. et al. Assessment of pharmacokinetic interactions between obeticholic acid and caffeine, midazolam, warfarin, dextromethorphan, omeprazole, rosuvastatin, and digoxin in phase 1 studies in healthy subjects // Adv Ther. 2017. Vol. 34, № 9. P. 2120–2138. https://doi.org/10.1007/s12325-017-0601-0.Edwards J. E., Eliot L., Parkinson A. et al. Assessment of pharmacokinetic interactions between obeticholic acid and caffeine, midazolam, warfarin, dextromethorphan, omeprazole, rosuvastatin, and digoxin in phase 1 studies in healthy subjects. Adv Ther. 2017;34(9):2120–2138. https://doi.org/10.1007/s12325017-0601-0.Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES PBC). URL: https://www.clinicaltrials.gov/study/NCT05292872 (accessed: 2.09.2024).Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES PBC). URL: https://www.clinicaltrials.gov/study/NCT05292872 (accessed: 2.09.2024).Murillo Perez C. F., Fisher H., Hiu S. et al. Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls // Gastroenterology. 2022. Vol. 163, № 6. P. 1630–1642.e3. https://doi.org/10.1053/j.gastro.2022.08.054.Murillo Perez C. F., Fisher H., Hiu S. et al. Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls. Gastroenterology. 2022;163(6):1630–1642.e3. https://doi.org/10.1053/j.gastro.2022.08.054.Zhang H., Dong M., Liu X. Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat // Exp Ther Med. 2021. Vol. 22, № 3. P. 991. https://doi.org/10.3892/etm.2021.10423.Zhang H., Dong M., Liu X. Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat. Exp Ther Med. 2021;22(3):991. https://doi.org/10.3892/etm.2021.10423.Yan M., Hou L., Cai Y. et al. Effects of intestinal FXR-related molecules on intestinal mucosal barriers in biliary tract obstruction // Front Pharmacol. 2022. Vol. 13:906452. https://doi.org/10.3389/fphar.2022.906452.Yan M., Hou L., Cai Y. et al. Effects of intestinal FXR-related molecules on intestinal mucosal barriers in biliary tract obstruction. Front Pharmacol. 2022;13:906452. https://doi.org/10.3389/fphar.2022.906452.Obeticholic acid for prevention in Barrett’s esophagus. https://www.clinicaltrials.gov/study/NCT04939051 (accessed: 2.09.2024).Obeticholic acid for prevention in Barrett’s esophagus. https://www.clinicaltrials.gov/study/NCT04939051 (accessed: 2.09.2024).Testing obeticholic acid for familial adenomatous polyposis. https://www.clinicaltrials.gov/study/NCT05223036 (accessed: 2.09.2024).Testing obeticholic acid for familial adenomatous polyposis. https://www.clinicaltrials.gov/study/NCT05223036 (accessed: 2.09.2024).Prikhodko V. A., Bezborodkina N. N., Okovityi S. V. Pharmacotherapy for Non-alcoholic fatty liver disease: Emerging targets and drug candidates // Biomedicines. 2022. Vol. 10, № 2. P. 274. https://doi.org/10.3390/biomedicines10020274.Prikhodko V. A., Bezborodkina N. N., Okovityi S. V. Pharmacotherapy for Non-alcoholic fatty liver disease: Emerging targets and drug candidates. Biomedicines. 2022;10(2):274. https://doi.org/10.3390/biomedicines10020274.Zhao J., Li B., Zhang K., Zhu Z. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2024. Vol. 103, № 7. P. e37271. https://doi.org/10.1097/MD.0000000000037271Zhao J., Li B., Zhang K., Zhu Z. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2024;103(7):e37271. https://doi.org/10.1097/MD.0000000000037271.FDA briefing document (NDA 212833). 2023. https://www.fda.gov/media/168215/download (accessed on 02 Sep 2024)FDA briefing document (NDA 212833). 2023. https://www.fda.gov/media/168215/download (accessed on 02 Sep 2024).Comparative study between obeticholic acid versus vitamin E in patients with non-alcoholic steatohepatitis. URL: https://www.clinicaltrials.gov/study/NCT05573204 (accessed: 2.09.2024).Comparative study between obeticholic acid versus vitamin E in patients with non-alcoholic steatohepatitis. URL: https://www.clinicaltrials.gov/study/NCT05573204 (accessed: 2.09.2024).European Union drug regulating authorities clinical trials database. URL: https://eudract.ema.europa.eu/ (accessed: 2.09.2024).European Union drug regulating authorities clinical trials database. URL: https://eudract.ema.europa.eu/ (accessed: 2.09.2024).Государственный реестр лекарственных средств. Обетихолевая кислота. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b83541bb-0351-4d3c-b21c4f8356742241 (дата обращения: 2.09.2024).Russian State Drug Register. Obeticholic acid. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b83541bb-0351-4d3c-b21c-4f8356742241 (accessed: 2.09.2024).

The authors declare that there are no conflicts of interest present.